Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Other Financing Activities

Financing cash flows not reported separately.

Evotec SENASDAQ: EVO

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities growth accelerates

Q1 FY2026 other financing activities of €7M (cash outflow) rose 780.9% year over year, ahead of the +310.9% change in trailing-twelve-month other financing activities. Sequentially, it fell 83.4% from the prior quarter. Over 3 fiscal years it compounded at +61.5% a year.

Context

  • Other financing activities amounted to 3.0% of revenue in FY2025, up 1.8 pp from a year earlier.
  • Other financing activities grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +780.9% holds above the trailing-twelve-month pace of +310.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€7M-83.4% QoQ
Last fiscal yearDec 2025
-€22.71M+142.9% YoY
LTMMar 2026
-€54.26M+310.9% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+780.9%——
1 year+142.9%——
3-year CAGR+61.5%——
5-year CAGR——
10-year CAGR——

Other Financing Activities history

EUR · from the cash flow

Latest · FY2025
(22.71M) EUR
Year-over-year change
-142.9%

Other Financing Activities vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +310.9% is the 4th highest of 11, against a peer median of +35.0%.
  • Other financing activities amounts to 7.3% of revenue for EVO, versus a peer median of 1.0%.
EVO Competitors
Other Financing Activities for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHVSPharvaris N.V.LTM Sep 2026€105.84M EUR+1070.0%+135.1%—
EVOEvotec SELTM Mar 2026€54.26M EUR+310.9%+61.5%7.3%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$21.6M USD+436.0%—23.9%
HROWHarrow Health, Inc.LTM Mar 2026$12.17M USD-2165.4%+374.7%4.5%
PCRXPacira BioSciences, Inc.LTM Mar 2026$11.98M USD-4604.5%+68.5%1.6%
ALVOAlvotechLTM Mar 2026$9.26M USD+119.0%—1.7%
TDOCTeladoc Health, Inc.LTM Mar 2026$6.96M USD+6462.3%+14.4%0.3%
SDGRSchrödinger, Inc.LTM Sep 2026$2.72M USD+288.3%—1.0%
TLRYTilray Brands, Inc.LTM Feb 2026$1.85M USD-49.0%-32.1%0.2%
NVCRNovoCure LimitedLTM Mar 2026$451K USD-100.5%—0.1%
AZTAAzenta, Inc.LTM Sep 2026$251K USD-96.1%-18.8%0.0%
Peer median (excluding EVO) —+35.0%+41.4%1.0%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Depreciation & Amortization67.61M83.2M92.98M101.62M95.55M
Deferred Income Tax5.07M21.7M3.32M2.1M14.11M
Stock-Based Compensation7.81M9.92M9.63M5.04M0
Change in Working Capital(2.28M)105.29M(9.94M)(68.21M)(58.4M)
Accounts Receivables(48.03M)(53.68M)00(27.6M)
Inventory(11.65M)(4.41M)00(9.18M)
Accounts Payables31.34M24.55M00(7.02M)
Other Working Capital26.06M138.83M(9.94M)(68.21M)(14.61M)
Other Non-Cash Items(171.47M)161.37M24.37M173.75M39.11M
Operating Cash Flow122.24M205.81M36.44M18.22M(9.06M)
Capital Expenditures(118.94M)(181.35M)(216M)(132.24M)(69.68M)
Acquisitions (Net)(21.09M)(83.82M)(20.16M)42.78M213.76M
Purchases of Investments(123.7M)(355.82M)(48.39M)(29.39M)(13.42M)
Sales of Investments27.25M205.17M260.36M35.67M38.87M
Other Investing Activities(7.38M)3.03M8.22M(2.78M)0
Investing Cash Flow(243.86M)(412.8M)(13.29M)(71.19M)159.86M
Debt Repayment14.77M(53.11M)84.6M(152.07M)(6.96M)
Common Stock Issued404.32M355K00(1.27M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.67M)(5.39M)(12.63M)(9.35M)(22.71M)
Financing Cash Flow398.43M(58.15M)71.96M(161.42M)(30.93M)
Effect of Forex Changes(66K)(19.04M)644K9.87M28.46M
Net Change in Cash276.75M(284.17M)95.75M(204.52M)148.32M
Free Cash Flow3.29M24.46M(179.56M)(114.02M)(78.74M)

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.